Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.

Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. Cancer J. 2017 Mar/Apr;23(2):131-137 Authors: Balan S, Finnigan J, Bhardwaj N Abstract Dendritic cells (DCs) are equipped for sensing danger signals and capturing, processing, and presenting antigens to naive or effector cells and are critical in inducing humoral and adaptive immunity. Successful vaccinations are those that activate DCs to elicit both cellular and humoral responses, as well as long-lasting memory response against the target of interest. Recently, it has become apparent that tumor cells can provide new sources of antigens through nonsynonymous mutations or frame-shift mutations, leading to potentially hundreds of mutation-derived tumor antigens (MTAs) or neoantigens. T cells recognizing MTA have been detected in cancer patients and can even lead to tumor regression. Designing MTA-specific vaccination strategies will have to take into account the adjuvant activity of DC subsets and the best formulation to elicit an effective immune response. We discuss the potential of human DCs to prime MTA-specific responses. PMID: 28410301 [PubMed - in process]
Source: Cancer Journal - Category: Cancer & Oncology Authors: Tags: Cancer J Source Type: research

Related Links:

Irreversible T cell exhaustion limits the efficacy of programmed cell death 1 (PD-1) blockade. We observed that dual CD40-TLR4 stimulation within a single tumor restored PD-1 sensitivity and that this regimen triggered a systemic tumor-specific CD8+ T cell response. This approach effectively treated established tumors in diverse syngeneic cancer models, and the systemic effect was dependent on the injected tumor, indicating that treated tumors were converted into necessary components of this therapy. Strikingly, this approach was associated with the absence of exhausted PD-1hi T cells in treated and distant tumors, while s...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Publication date: Available online 20 July 2019Source: Seminars in Cancer BiologyAuthor(s): Nancy A. Espinoza-Sánchez, Martin GötteAbstractOver the past few decades, understanding how tumor cells evade the immune system and their communication with their tumor microenvironment, has been the subject of intense investigation, with the aim of developing new cancer immunotherapies. The current therapies against cancer such as monoclonal antibodies against checkpoint inhibitors, adoptive T-cell transfer, cytokines, vaccines, and oncolytic viruses have managed to improve the clinical outcome of the patients. However,...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 20 July 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Ashlynn L.Z. Lee, Chuan Yang, Shujun Gao, James L. Hedrick, Yi Yan YangAbstractProlonged vaccine release enables gradual immunostimulation, providing long-term immunity. Herein, Vitamin E- PEG-Vitamin E triblock ‘ABA’ hydrogel, which is formed through physical cross-linking of flower-shaped micelles and can reside in vivo for>17 weeks, was employed for delivery of cancer preventive vaccines to provide sustained anticancer immunity. Mice vaccinated with hydrogel formulations produced a sign...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
This study elucidates the potential to use mitochondria from different donors (PAMM) to treat UVR stress and possibly other types of damage or metabolic malfunctions in cells, resulting in not only in-vitro but also ex-vivo applications. Gene Therapy in Mice Alters the Balance of Macrophage Phenotypes to Slow Atherosclerosis Progression https://www.fightaging.org/archives/2019/07/gene-therapy-in-mice-alters-the-balance-of-macrophage-phenotypes-to-slow-atherosclerosis-progression/ Atherosclerosis causes a sizable fraction of all deaths in our species. It is the generation of fatty deposits in blood vessel...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
Condition:   Triple-negative Breast Cancer Interventions:   Biological: AE37 Peptide vaccine;   Biological: Pembrolizumab Sponsors:   Antigen Express, Inc;   Merck Sharp & Dohme Corp.;   NSABP Foundation Inc Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
[New Times] After registering 93 per cent coverage of vaccination against cervical cancer, Rwanda has signed a deal aimed at rolling out new technologies to improve accessibility to screening and diagnosis of the disease.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
.
Source: OncoImmunology - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: PFSl was significantly improved in ICT-107 treated patients with maintenance of QoL. Patients in the HLA-A2 subgroup showed increased ICT-107 activity clinically and immunologically. PMID: 31320597 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Anixa to Host a Conference Call Thursday, July 18, 2019, 4:30 p.m. ET to Discuss Agreement SAN JOSE, Calif., July 17, 2019 -- (Healthcare Sales &Marketing Network) -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessin... Biopharmaceuticals, Oncology, Licensing Anixa Biosciences, breast cancer vaccine, triple negative breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Medical Training Application Service | Vaccines